REG - Oxford Biomedica PLC - OXB Secures New Loan Facility with Oaktree

Oxford BioMedicaAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250801:nRSA5818Ta&default-theme=true

RNS Number : 5818T  Oxford Biomedica PLC  01 August 2025

 

 

 

OXB Secures New Four-Year Term Loan Facility with Oaktree

-       Up to $125 million Oaktree loan facility to support OXB's global
CDMO operations and growth strategy

-       $60 million upfront to repay existing $50 million loan facility
and for general corporate purposes

-       Facility provides flexibility to draw down additional funds to
support future business needs, if required

 

Oxford, UK - 1 August 2025: OXB (LSE: OXB) ("the Company"), a global quality
and innovation-led cell and gene therapy CDMO, today announces that it has
secured a new four-year loan facility of up to $125 million (the "New Oaktree
Loan"), provided by funds managed by Oaktree Capital Management, L.P.
("Oaktree"), a long-term capital partner to OXB. The new facility will
strengthen the Company's financial foundation by refinancing its existing $50
million loan facility and providing financial flexibility to support OXB's
global CDMO operations and the delivery of its growth strategy.

 

The New Oaktree Loan facility includes $60 million upfront funding available
at close, which will be used to repay the existing $50 million four-year term
loan facility with Oaktree (previously announced in October 2022
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1631983)
) and for general corporate purposes. The facility also includes the option to
draw down a further $25 million, subject to customary conditions, and an
additional $40 million, subject to achieving certain revenue milestones -
providing financial flexibility to support future business needs, if required.

 

Terms of the New Oaktree Loan are broadly similar to the prior four-year loan
facility and include standard and customary provisions relating to mandatory
and voluntary prepayments, covenants, representations and warranties. The New
Oaktree Loan will not amortise, with the full aggregate principal and
outstanding amount being repayable on the final maturity date in 2029.

 

Consistent with the terms of the existing facility, the New Oaktree Loan will
be secured by substantially all of the assets of the Company and its
wholly-owned subsidiaries and be guaranteed by the Company's wholly-owned
subsidiaries, with customary exceptions.

 

Dr. Lucinda Crabtree, Chief Financial Officer of OXB, commented: "Refinancing
this facility marks an important step in strengthening our financial agility
as we continue to execute our growth strategy. Oaktree's continued support
reflects their long-standing confidence in OXB's leading position in the CDMO
viral vector market and enables us to remain focused on enhancing our
capabilities, delivering on our strategic objectives and creating value for
our clients and stakeholders."

 

Aman Kumar, Co-Portfolio Manager for Oaktree's Life Sciences Lending platform,
commented "We are delighted to extend our relationship with OXB through this
debt refinancing. Over the course of our three previous investments, we have
had an opportunity to witness first-hand the progress that the Company has
made to establish itself as a global leader in the cell and gene therapy CDMO
industry. We look forward to continuing to support the Company as it executes
on its multi-vector, multi-site strategy."

 

 

Jefferies International Limited was the debt advisor to the Company, with King
& Spalding LLP serving as legal counsel to OXB in connection with the
refinancing. McDermott Will & Emery LLP served as legal counsel to
Oaktree.

 

-Ends-

 

Enquiries:

 

OXB:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com (mailto:ir@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), a dual-plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer and
packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

About Oaktree

 

Oaktree is a leader among global investment managers specializing in
alternative investments, with $209 billion in assets under management as of
June 30, 2025. The firm emphasizes an opportunistic, value-oriented, and
risk-controlled approach to investments in credit, equity, and real estate.
The firm has more than 1,200 employees and offices in 26 cities worldwide. For
additional information, please visit Oaktree's website at
http://www.oaktreecapital.com/ (http://www.oaktreecapital.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKDBQPBKKPFK